Gix Internet (GIXI) has initiated voluntary delisting from the Tel Aviv Stock Exchange while retaining its Nasdaq listing. The final TASE trading day is expected to be January 25, 2027, with delisting expected on or about January 27, 2027. The board approved the move to potentially enhance Nasdaq liquidity and focus investor relations on U.S. capital markets. All ordinary shares traded on TASE may be transferred to Nasdaq.
Gix Internet (GIXI) announced two quantum-computing technology milestones at Quantum X Labs, in which it holds an approximately 13% stake.
QXL’s error-correction decoder is running on NVIDIA CUDA-Q. On Google’s public hardware dataset, it made 12.7% fewer logical errors than the standard PyMatching decoder at code distance 3 and 12.1% fewer at distance 5. A separate streaming evaluation showed approximately 6% and 9% lower observed logical error rates, respectively.
QuantumQ Security’s LayerQake reduced measurement bias from approximately 11%–15% to below 6% and maximum cumulative error 15- to 21-fold across three IBM processors. QXL plans a real-time error-correction test using an NVIDIA NVQLink connection. Gix does not control QXL and has not independently verified its reported technical results.
GIX Internet (GIXI) expanded its Deliverz.AI hospital robot deployment at Sheba Medical Center to additional transport workflows in October 2026. The new workflows move bone marrow specimens to the laboratory and donated blood to the blood bank. Commercial operations began in December 2025, and more than 9,000 autonomous missions were completed as of October 2026.
Average chemotherapy medication delivery time fell from approximately 40 minutes to approximately 14 minutes over 11 months. Sheba's public tender permits up to 30 robots, with 3 currently deployed. GIX plans further hospital routes and additional commercial deployments, particularly in the U.S. It has not yet commercially deployed the platform outside healthcare.
Gix Internet (GIXI) announced that its subsidiary deliverz.ai’s autonomous robots have begun delivering blood and bone marrow at Sheba Medical Center.
The workflows expand an existing robotic logistics project delivering chemotherapy medications. Robots transport bone marrow specimens from hematology to the laboratory and donated blood from the donation center to the blood bank. A unified platform coordinates robots and human resources. The company aims to reduce transport delays, improve traceability and shorten laboratory turnaround times. Further expansion is planned to include additional medication and diagnostic specimen transport workflows.
Gix Internet (GIXI) has signed a $500,000 strategic investment in U.S.-based Physical AI robotics company Ottonomy via a simple agreement for future equity (SAFE), advancing its plan to build one intelligent management layer for robots, people and autonomous systems.
The SAFE gives Gix contractual rights to receive Ottonomy equity upon certain future financing or other specified events and may convert upon qualifying financings in accordance with its terms. On August 4, 2026, the companies also entered a non-binding letter of intent that contemplates additional Gix investments that could lead to a strategic, and potentially majority, ownership interest in Ottonomy, subject to due diligence, financing, definitive agreements, approvals and customary closing conditions. The SAFE investment is expected to close during the week of September 16, 2026, subject to customary conditions.
Gix Internet (GIXI) launched a new corporate website outlining its strategy for one intelligent, AI-powered management and orchestration layer for robots, people and autonomous systems. The site targets hospitals, potential partners and investors and highlights the current commercial deployment of this platform in hospital logistics via wholly owned subsidiary Deliverz.ai.
Deliverz.ai coordinates autonomous robots and human transport teams for internal deliveries and is designed to integrate with existing hospital infrastructure. At Sheba Medical Center, the system has been in continuous commercial use since December 2025, completing more than 7,000 autonomous missions and cutting chemotherapy delivery time from 40 minutes to 14. Sheba selected Deliverz.ai under a public tender allowing potential deployment of up to 30 robots. Deliverz.ai holds two granted physical-AI navigation patents registered in Israel, Europe and Korea, with further applications under review in the United States and Japan.